The letter responds to comment on Identification of stage I/IIA melanoma patients at high risk of disease relapse using a clinicopathologic and gene expression model.

Eggermont, Alexander M M; Bellomo, Domenico; Dwarkasing, Jvalini; Meerstein-Kessel, Lisette; Meves, Alexander

The letter responds to comment on Identification of stage I/IIA melanoma patients at high risk of disease relapse using a clinicopathologic and gene expression model.

Eggermont, Alexander M M; Bellomo, Domenico; Dwarkasing, Jvalini; Meerstein-Kessel, Lisette; Meves, Alexander.

Eggermont AMM; Princess Máxima Center, Utrecht, the Netherlands; University Medical Center Utrecht, Utrecht, the Netherlands.
Bellomo D; SkylineDx B.V., Rotterdam, the Netherlands.
Dwarkasing J; SkylineDx B.V., Rotterdam, the Netherlands.
Meerstein-Kessel L; SkylineDx B.V., Rotterdam, the Netherlands.
Meves A; Mayo Clinic, Rochester, MN, USA. Electronic address: meves.alexander@mayo.edu.

Eur J Cancer ; 157: 518-519, 2021 11.

Article in English | MEDLINE | ID: covidwho-1536524

Subject(s)

Melanoma; Skin Neoplasms; Gene Expression; Humans; Melanoma/genetics; Recurrence; Skin Neoplasms/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Type of study: Prognostic study Limits: Humans Language: English Journal: Eur J Cancer Year: 2021 Document Type: Article Affiliation country: J.ejca.2021.08.042

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google